ENDRA Life Sciences Inc. and VGI Health Technology Limited announce the signing of a collaboration agreement to incorporate ENDRA's proprietary TAEUS technology to support patient screening and biomarker measurement during VGI's upcoming Phase 2 study of IVB001 in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 AUD | -33.33% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 1.83M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- VTL Stock
- News VGI Health Technology Limited
- ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study